News
SPRY
13.35
+0.45%
0.06
ARS Pharmaceuticals's Earnings: A Preview
Benzinga · 12h ago
ARS Pharmaceuticals Inc <SPRY.OQ> expected to post a loss of 35 cents a share - Earnings Preview
Reuters · 1d ago
Weekly Report: what happened at SPRY last week (0505-0509)?
Weekly Report · 1d ago
ARS Pharmaceuticals’ neffy 1mg now available across U.S.
TipRanks · 6d ago
ARS PHARMACEUTICALS INC: CASH PRICE FOR NEFFY IS $199 FOR TWO DOSES ON GOODRX WEBSITE
Reuters · 6d ago
ARS Pharmaceuticals: Strategic Partnership and Market Expansion Drive Buy Rating
TipRanks · 05/06 06:06
ARS Pharmaceuticals (SPRY) Gets a Buy from Scotiabank
TipRanks · 05/05 11:07
Weekly Report: what happened at SPRY last week (0428-0502)?
Weekly Report · 05/05 10:56
Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential
Seeking Alpha · 05/04 20:32
William Blair Reaffirms Their Buy Rating on ARS Pharmaceuticals (SPRY)
TipRanks · 05/02 16:25
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY) and Stryker (SYK)
TipRanks · 05/02 16:20
ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy
Seeking Alpha · 05/02 13:47
ARS Pharmaceuticals Entered Into An Agreement With ALK-Abelló To Co-promote Neffy (Epinephrine Nasal Spray) For Type I Allergic Reactions, To Up To 9,000 Pediatricians, For An Upfront Of $145M
Benzinga · 05/02 12:06
ARS Pharmaceuticals Air Lease ALK-Abello
TipRanks · 05/02 12:05
ARS PHARMACEUTICALS ANNOUNCES CO-PROMOTION AGREEMENT WITH PARTNER AND GLOBAL ALLERGY LEADER ALK-ABELLÓ A/S TO EXPAND REACH OF NEFFY® (EPINEPHRINE NASAL SPRAY) TO ADDITIONAL U.S. PEDIATRICIANS
Reuters · 05/02 12:00
ARS PHARMACEUTICALS INC - PHARMA RECEIVED $145 MILLION UPFRONT FROM ALK
Reuters · 05/02 12:00
ARS Pharmaceuticals Has A Blockbuster Candidate
Seeking Alpha · 04/30 10:51
Weekly Report: what happened at SPRY last week (0421-0425)?
Weekly Report · 04/28 11:03
Weekly Report: what happened at SPRY last week (0414-0418)?
Weekly Report · 04/21 11:03
Weekly Report: what happened at SPRY last week (0407-0411)?
Weekly Report · 04/14 10:54
More
Webull provides a variety of real-time SPRY stock news. You can receive the latest news about ARS Pharms through multiple platforms. This information may help you make smarter investment decisions.
About SPRY
More
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Recently
Symbol
Price
%Change